Navigation Links
FDA, NIH to Speak at CBI's 14th Annual Registries and Post-Approval Studies Congress

WOBURN, Mass., Aug. 18, 2011 /PRNewswire/ -- CBI is pleased to announce the full agenda for its industry-leading, 14th Annual Registries and Post-Approval Studies Congress, being held September 20-22, 2011 in Philadelphia, PA. The program, sponsored by REGISTRAT-MAPI, boasts an impressive speaker lineup from Celgene, Covidien, FDA, Forest, Ironwood Pharmaceuticals, Merck, NIH, Pfizer, Takeda Europe and many more.

Attendees have the opportunity to customize their congress experience by choosing between breakout sessions, concurrent tracks and participating in interactive panel discussions. Session highlights include:

  • Driving Value in Research by Designing, Implementing and Improving Patient Registries
  • Optimizing Post-Marketing Requirements and REMS
  • Developing Strategies to Benefit Sponsor and Regulatory Authorities
  • Complying with U.S., EU and Canadian Post-Approval Requirements
  • Responding to Increased Payer Requirements to Support Reimbursement Decisions
  • Maximizing the Value of Registries and Other Post-Approval Studies

Industry leaders will be afforded the exclusive opportunity to participate in the Invitation-Only Post-Approval Executive Summit hosted by REGISTRAT-MAPI. This 5th Annual Summit provides a unique forum for senior-level executives involved in post-approval studies, including clinical, medical, safety and regulatory to address the strategic issues they face.

CBI's Post-Approval Studies series is the industry's premier source for cutting-edge content and unparalleled programming related to post-approval studies. For more information on the conference or to view the entire agenda, please visit

About CBI:

CBI, a subsidiary of Advanstar, is the leading provider of market-driven, unbiased conferences for the pharmaceutical, biotechnology, medical device and healthcare industries. CBI offers specialized information presented in interactive formats by thought leaders and regulators. For more information, please visit

About REGISTRAT-MAPI, Global Foundation Sponsor:

REGISTRAT-MAPI provides strategic and operational solutions for our clients in the design and implementation of Late Phase studies. REGISTRAT-MAPI is the pharmaceutical industry's largest global CRO dedicated exclusively to real-world clinical research. With more than 250 experienced professionals, REGISTRAT-MAPI has served the pharmaceutical and medical device industries for more than 20 years. For more information, please visit

For additional information or media inquiries, please contact Emily Forest, CBI Marketing Manager, at 339-298-2156 or Amy Wynn, REGISTRAT-MAPI Manager, Global Marketing, at 215-568-0121.

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Accuray Incorporated to Speak at 2011 Wedbush Life Sciences: Management Access Conference
2. Pathogenica CSO Speaks at IBC Life Sciences Drug Discovery & Diagnostic Development Week
3. Qteros Management to Speak at June Conferences
4. CBI Keynote Speakers on Cover of Time Magazine
5. Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing
6. Pam Marrone to Speak at Ag 2.0 Conference
7. Pharma ChemOutsourcing 2011 Unveils First Wave of 50 Biotech Chemist Speakers for September 12-15 Show in New Jersey
8. Science advisor to the US EPA to speak to industry, academic leaders on sustainability innovations
9. PRA International Expert to Speak at China Drug Safety Summit
10. Tianyins Dr. James Jiayuan Tong is Invited to Speak at the CFO China Summit 2011 on January 19, 2011 at the St. Regis Hotel, Beijing
11. Accuray Incorporated to Speak at Seventh Annual Lazard Capital Markets Healthcare Conference
Post Your Comments:
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts ... they believe could be a new and helpful biomarker for malignant pleural mesothelioma. ... here to read it now. , Biomarkers are components in the blood, ...
(Date:6/27/2016)... ... 27, 2016 , ... Newly created 4Sight Medical Solutions ... the healthcare market. The company's primary focus is on new product introductions, to ... that are necessary to help companies efficiently bring their products to market. , ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
Breaking Biology News(10 mins):